<DOC>
	<DOCNO>NCT01951482</DOCNO>
	<brief_summary>This multi-center phase II randomize control study ass efficacy Pemetrexed/cisplatin without Bevacizumab patient brain metastasis non-small cell lung cancer ( NSCLC ) harbor EGFR wild type intracranial PFS ( iPFS ) , also PFS , DCR OS.The side effect evaluate well .</brief_summary>
	<brief_title>Pemetrexed/Cisplatin With Without Bevacizumab Brain Metastases From Non Squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patient confirm stage IV non squamous NSCLC EGFR wild type brain metastasis pathologic histology cytology 2 . Patients never receive therapy ( include chemotherapy , WBRT , Bevacizumab ) diagnose brain metastasis 3 . Appraisable disease , presence least three lesion longest diameter &lt; 10 mm brain MRI 4 . Adult patient ( ≥ 18 year ≤75 year ) . ECOG Performance Status 0 1 Life expectancy least 12 weeks. , Haemoglobin ³ 10.0 g/dl , Absolute neutrophil count ( ANC ) ³1.5 x 109/L , platelet ³ 100 x 109/L . Total bilirubin £ 1.5 x upper limit normal ( ULN ) . ALT AST &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastasis . Creatinine clearance ³ 60ml/min ( calculate accord Cockcroftgault formula ) . 5 . Patients contraceptive period trial 1 . Mixed , nonsmall cell small cell tumour mix adenosquamous carcinoma predominant squamous component . 2 . History haemoptysis 3 . Evidence tumour invade major blood vessel image . 4 . Patient receive irradiation brain . Patient meningeal metastasis confirm MRI cytology test cerebrospinal fluid . 5 . Previous radiotherapy . 6 . Serious uncontrolled coagulation disorder thrombiembolic complication within 6 month prior study start history serious bleeding complication . 7 . Major surgical procedure within 4 week prior study entry . 8 . Minor surgery , include insertion indwelling catheter , within 24 hour prior first bevacizumab infusion . 9 . Nonhealing wound , active peptic ulcer bone fracture . 10 . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>